Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Metabolic Dysfunction-Associated Steatohepatitis

Metabolic Dysfunction-Associated Steatohepatitis

Part of Metabolic Dysfunction-Associated Steatotic Liver Disease

Subtypes of Metabolic Dysfunction-Associated Steatohepatitis

Metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis 1 Metabolic dysfunction-associated steatohepatitis cirrhosis 1 Non-cirrhotic metabolic dysfunction-associated steatohepatitis 1

34 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Metabolic Dysfunction-Associated Steatohepatitis

60 trials tracked for Metabolic Dysfunction-Associated Steatohepatitis: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 1022 citations.

60Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 45 Phase 1 3 Other / NA 8
  1. Phase 4 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed · 1,022 cited
  2. Phase 4 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed · 312 cited
  3. Phase 3 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Completed
  4. Phase 3 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH Completed
  5. Phase 2 Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) Completed
  6. Phase 2 Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy Completed
Show 44 more trials
  1. Phase 2 Pentoxifylline in Patients With Nonalcoholic Steatohepatitis Completed
  2. Phase 2 A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases Completed
  3. Phase 2 A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus Completed
  4. Phase 2 Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis Completed
  5. Phase 2 Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis Completed
  6. Phase 2 Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) Completed
  7. Phase 2 Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) Completed
  8. Phase 2 A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) Completed
  9. Phase 2 Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis Completed
  10. Phase 2 Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Completed
  11. Phase 2 A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH Completed
  12. Phase 2 Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects Completed
  13. Phase 2 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Completed
  14. Phase 2 A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) Completed
  15. Phase 2 Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis Completed
  16. Phase 2 BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH Completed
  17. Phase 2 Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Completed
  18. Phase 2 A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) Completed
  19. Phase 2 Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis Completed
  20. Phase 2 CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Completed
  21. Phase 2 A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH Completed
  22. Phase 2 Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis Completed
  23. Phase 2 Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) Completed
  24. Phase 2 Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) Completed
  25. Phase 2 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis Completed
  26. Phase 2 Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis Completed
  27. Phase 2 A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH Completed
  28. Phase 2 An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis Completed
  29. Phase 2 Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. Completed
  30. Phase 2 Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension Completed
  31. Phase 2 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis Completed
  32. Phase 2 Vitamin E Dosing Study Completed
  33. Phase 2 Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis Completed
  34. Phase 2 Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease Completed
  35. Phase 2 A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Completed
  36. Phase 2 Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) Completed
  37. Phase 2 JKB-121 for the Treatment of Nonalcoholic Steatohepatitis Completed
  38. Phase 2 Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH) Completed
  39. Phase 2 A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) Completed
  40. Phase 2 A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage Completed
  41. Phase 2 Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH Completed
  42. Phase 2 Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis Completed
  43. Phase 2 A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH Completed
  44. Phase 1 A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) Completed

Showing the 50 most-cited and recently-updated of 60 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Proposed pathway for systematic MASLD/MASH assessment in type 2 diabetes
Diabetes & Endocrinology Sys. Review
Proposed pathway for systematic MASLD/MASH assessment in type 2 diabetes New Pathway Proposed to Manage Liver Disease in Diabetes Patients
This narrative review proposes a structured, risk-adapted outpatient pathway for MASLD/MASH assessment in patients with type 2 diabetes, sta…
A new proposed management plan aims to help people with type 2 diabetes identify and assess liver conditions more systematically.
Frontiers Jul 30, 2026
Subcutaneous semaglutide more than doubles the likelihood of NASH resolution without fibrosis progression
Gastroenterology Meta-analysis
Subcutaneous semaglutide more than doubles the likelihood of NASH resolution without fibrosis progression Semaglutide shows promise for treating fatty liver disease and NASH
This meta-analysis of randomized controlled trials evaluated subcutaneous semaglutide in adults with NAFLD or NASH. The analysis found signi…
A new analysis shows that semaglutide can help resolve liver inflammation and improve metabolic health in people with fatty liver disease.
NEJM Jul 26, 2026
Immune crosstalk between innate and adaptive compartments drives inflammatory mechanisms in MASLD and MASH progression
Gastroenterology Sys. Review
Immune crosstalk between innate and adaptive compartments drives inflammatory mechanisms in MASLD and MASH progression Immune system crosstalk drives fatty liver disease progression
This systematic review examines the role of immune system interactions in metabolic dysfunction-associated steatotic liver disease (MASLD) a…
A new review reveals that immune cells talking to each other may be what pushes fatty liver disease toward severe liver damage.
Frontiers Jun 30, 2026
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
Diabetes & Endocrinology Meta-analysis
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis New analysis shows SGLT2 inhibitors may help liver scarring improve in adults with fatty liver disease
A network meta-analysis of 34 trials found FGF21 analogs and SGLT2 inhibitors ranked highest for improving liver fibrosis in MASH, with GLP-…
A large review of trials found SGLT2 inhibitors ranked highest for reducing liver scarring. These drugs also showed good safety and balanced…
Frontiers Jun 4, 2026
Narrative review explores immunometabolic networks in MASH and MASLD
Nutrition & Obesity Medicine Sys. Review
Narrative review explores immunometabolic networks in MASH and MASLD Future treatments for fatty liver disease may use personalized networks to guide care
This narrative review discusses metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease (MASLD), focusing on imm…
New ideas for treating fatty liver disease focus on personalized networks and multi-target approaches to guide future drug development.
Frontiers May 27, 2026
Narrative review explores macrophage reprogramming for liver fibrosis and MASH
Oncology Sys. Review
Narrative review explores macrophage reprogramming for liver fibrosis and MASH Scientists explore new ways to reprogram liver cells to heal damaged tissue and stop scarring
This narrative review summarizes macrophage reprogramming strategies for liver fibrosis and MASH. Approaches include gene modulation, pharma…
A recent review looks at fresh methods to change how liver immune cells behave. These changes could help heal liver scarring and improve hea…
Frontiers May 17, 2026
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease
Drug Pipeline Sys. Review
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease New Hope for Fatty Liver Disease Targets Hidden Triglyceride Problem
This narrative review synthesizes evidence on triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease. …
• Lowering triglycerides may directly heal fatty liver damage • Helps millions with metabolic syndrome and stubborn liver fat • Most treatme…
Frontiers May 12, 2026
Network meta-analysis of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis
Gastroenterology Meta-analysis
Network meta-analysis of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis New therapies show promise for liver disease without cirrhosis
This network meta-analysis of 12,787 adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis from phase 2-3 trials evalua…
Treatments targeting metabolism and insulin sensitivity helped more people with early liver disease than placebo, based on a large review of…
May 10, 2026
Meta-analysis of placebo responses in metabolic dysfunction-associated steatohepatitis trials reveals modest natural resolution rates and low progression risk
Gastroenterology Meta-analysis
Meta-analysis of placebo responses in metabolic dysfunction-associated steatohepatitis trials reveals modest natural resolution rates and low progression risk New meta-analysis shows how many patients improve on placebo for MASH
This systematic review and meta-analysis examined placebo outcomes in patients with metabolic dysfunction-associated steatohepatitis.
This analysis of 6,880 patients reveals natural improvement rates in metabolic dysfunction-associated steatohepatitis when no active drug is…
May 1, 2026
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
Diabetes & Endocrinology Meta-analysis
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
This systematic review and network meta-analysis evaluates interventions for metabolic dysfunction-associated steatotic liver disease and st…
A new analysis suggests tirzepatide, semaglutide, and surgery might help resolve fatty liver disease without worsening scarring in adults wi…
May 1, 2026
Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis
Gastroenterology Meta-analysis
Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis AI models help doctors spot liver disease with high accuracy
This systematic review and meta-analysis of 106 studies assessed machine learning (ML) and deep learning (DL) models for diagnosing metaboli…
New computer tools can diagnose fatty liver disease and scarring with impressive accuracy. This review analyzed data from many studies to se…
May 1, 2026
Meta-analysis compares FAST and MAST scores for MASH with significant fibrosis diagnosis
Rheumatology Meta-analysis
Meta-analysis compares FAST and MAST scores for MASH with significant fibrosis diagnosis New Scans May Spot Dangerous Liver Disease Without a Biopsy
This meta-analysis of four studies evaluated FibroScan-AST (FAST) and MRI-AST (MAST) scores versus liver biopsy for diagnosing metabolic…
These new scan-based scores could help doctors find dangerous liver scarring sooner, without the need for a painful needle biopsy.
Frontiers Apr 23, 2026

Research across Metabolic Dysfunction-Associated Steatotic Liver Disease

Related studies from across the Metabolic Dysfunction-Associated Steatotic Liver Disease family.

Efficacy of GLP-1 Receptor Agonists in Managing MASLD and MASH Clinical Outcomes
Diabetes & Endocrinology Meta-analysis
Efficacy of GLP-1 Receptor Agonists in Managing MASLD and MASH Clinical Outcomes GLP-1 Drugs Linked to Less Liver Fat and Weight Loss
GLP-1 receptor agonists demonstrate significant reductions in liver fat, body weight, and transaminases in patients with MASLD or MASH.
A pooled analysis of 795 adults links GLP-1 drugs to less liver fat, lower liver enzymes, and modest weight loss in fatty liver disease.
NEJM Oct 27, 2026
mpMRI markers of liver disease are associated with lower health-related quality of life in MASH
Gastroenterology RCT
mpMRI markers of liver disease are associated with lower health-related quality of life in MASH Liver imaging markers linked to lower quality of life
This multinational real-world randomized controlled trial of 802 patients with suspected MASLD/MASH found that patients with MASH reported l…
New research shows that specific liver imaging markers are linked to lower quality of life and higher anxiety in patients with liver disease…
Oct 24, 2026
Short-chain fatty acids and intestinal macrophages modulate metabolism in metabolic syndrome and obesity
Nutrition & Obesity Medicine Sys. Review
Short-chain fatty acids and intestinal macrophages modulate metabolism in metabolic syndrome and obesity Short Chain Fatty Acids May Help Manage Metabolic Syndrome
This narrative review explores how short-chain fatty acids (SCFAs) like butyrate, acetate, and propionate influence intestinal macrophage im…
Short-chain fatty acids like butyrate may influence how the body handles inflammation and metabolism in people with obesity and insulin resi…
Frontiers Oct 23, 2026
cGAS-STING pathway serves as a central axis for innate immune activation in MASLD and HCC
Drug Pipeline Sys. Review
cGAS-STING pathway serves as a central axis for innate immune activation in MASLD and HCC New research identifies a key immune pathway in fatty liver disease
This systematic review explores the role of the cGAS-STING pathway in metabolic dysfunction-associated steatotic liver disease and hepatocel…
A specific immune pathway called cGAS-STING may play a major role in how fatty liver disease progresses and leads to serious complications.
Frontiers Oct 16, 2026
Hepatocyte senescence and SASP signaling contribute to inflammatory and fibrogenic remodeling in MASLD
Diabetes & Endocrinology Sys. Review
Hepatocyte senescence and SASP signaling contribute to inflammatory and fibrogenic remodeling in MASLD Liver Cell Aging May Drive Fatty Liver Disease
This narrative review examines the role of hepatocyte senescence and SASP signaling in metabolic dysfunction-associated steatotic liver dise…
A new review suggests aging liver cells may help drive fatty liver disease, but human evidence is still limited.
Frontiers Oct 15, 2026
Higher histologic liver fibrosis stages correlate with increased risk of cirrhosis and hepatic decompensation
Gastroenterology Meta-analysis
Higher histologic liver fibrosis stages correlate with increased risk of cirrhosis and hepatic decompensation Liver Fibrosis Stages Linked to Higher Risk of Liver Failure
This meta-analysis of 32 studies evaluates the association between histologic liver fibrosis stages and clinical outcomes in patients with M…
Higher stages of liver fibrosis are linked to a significantly increased risk of liver failure and death in patients with fatty liver disease…
Oct 3, 2026
Mediterranean diet reduces BMI and triglycerides in patients with NAFLD and MASLD
Gastroenterology Meta-analysis
Mediterranean diet reduces BMI and triglycerides in patients with NAFLD and MASLD Mediterranean diet shows modest benefits for fatty liver disease
This meta-analysis of 980 patients with NAFLD/MASLD found that a Mediterranean diet significantly reduced BMI (SMD -0.43) and triglycerides …
A Mediterranean diet can lower body mass index and triglycerides in people with fatty liver disease, though other metabolic markers stayed t…
Oct 2, 2026
Optimal ELF cutoffs identify significant fibrosis and cirrhosis in patients with MASLD
Gastroenterology Meta-analysis
Optimal ELF cutoffs identify significant fibrosis and cirrhosis in patients with MASLD New test cutoffs help identify liver scarring in fatty liver disease
This meta-analysis of 37 cohorts from 34 studies evaluates the Enhanced Liver Fibrosis (ELF) Test for identifying fibrosis stages in MASLD. …
New data helps doctors use the ELF test to better identify different stages of liver scarring in patients with fatty liver disease.
Oct 2, 2026
Hepatic macrophage metabolic reprogramming and bidirectional signaling dictate the balance between liver injury and regeneration
Gastroenterology Sys. Review
Hepatic macrophage metabolic reprogramming and bidirectional signaling dictate the balance between liver injury and regeneration New research identifies how liver cells communicate during chronic disease
This systematic review synthesizes the role of hepatic macrophages in metabolic dysfunction-associated steatotic liver disease, alcohol-asso…
New research reveals how specific immune cells in the liver switch between causing inflammation and repairing tissue damage.
Frontiers Sep 30, 2026
Multidisciplinary interventions and Mediterranean diet adherence may modestly reduce BMI Z-score in pediatric obesity
Psychiatry Sys. Review
Multidisciplinary interventions and Mediterranean diet adherence may modestly reduce BMI Z-score in pediatric obesity Mediterranean diet and behavior changes help manage childhood obesity
This narrative review synthesizes evidence regarding the impact of Mediterranean diet (KIDMED) adherence and multidisciplinary interventions…
A Mediterranean-style diet combined with team-based care shows promise in reducing weight and improving health for children with obesity.
Frontiers Sep 22, 2026
Subclinical humoral immune dysfunctions may drive gut-liver axis breakdown in pediatric MASLD
Diabetes & Endocrinology Sys. Review
Subclinical humoral immune dysfunctions may drive gut-liver axis breakdown in pediatric MASLD Immune system issues may drive liver disease in children
This mini-review explores the role of subclinical humoral immune dysfunctions, such as partial secretory IgA or IgG subclass deficiencies, i…
New research suggests that hidden immune system weaknesses could be a major driver of liver damage in children with fatty liver disease.
Frontiers Sep 18, 2026
MASLD in people living with HIV may represent a distinct immunometabolic condition with rising prevalence
Gastroenterology Sys. Review
MASLD in people living with HIV may represent a distinct immunometabolic condition with rising prevalence HIV Patients Face Rising Fatty Liver Risk, Review Finds
This narrative review examines the rising burden of metabolic dysfunction-associated steatotic liver disease (MASLD) in people living with H…
Fatty liver disease is rising among people with HIV, even when antiretroviral therapy works well, a new review reports.
Frontiers Sep 17, 2026

Questions about Metabolic Dysfunction-Associated Steatohepatitis

Can machine learning diagnose metabolic dysfunction-associated steatohepatitis and fibrosis?

Yes, machine learning models show good accuracy for diagnosing MASH and fibrosis, with pooled AUROCs around 0.83-0.84, but they are not yet ready to replace liver biopsy in clinical practice.

Full answer →
Which drugs work best for non-cirrhotic metabolic dysfunction-associated steatohepatitis?

For non-cirrhotic MASH, drugs targeting metabolism and insulin sensitivity (e.g., tirzepatide, semaglutide) work best, but lifestyle changes and weight loss are foundational.

Full answer →
Can lowering triglycerides help treat metabolic dysfunction-associated steatohepatitis?

Yes, lowering triglycerides may help treat MASH by reducing liver fat and improving inflammation, but more research is needed to confirm long-term benefits.

Full answer →